Download MendeleyA lung-selective delivery of mRNA encoding broadly neutralizing antibody against SARS-CoV-2 infection.
Tai, W., Yang, K., Liu, Y., Li, R., Feng, S., Chai, B., Zhuang, X., Qi, S., Shi, H., Liu, Z., Lei, J., Ma, E., Wang, W., Tian, C., Le, T., Wang, J., Chen, Y., Tian, M., Xiang, Y., Yu, G., Cheng, G.(2023) Nat Commun 14: 8042-8042
- PubMed: 38052844
- DOI: https://doi.org/10.1038/s41467-023-43798-8
- Primary Citation of Related Structures:
8J1T, 8J1V - PubMed Abstract:
The respiratory system, especially the lung, is the key site of pathological injury induced by SARS-CoV-2 infection. Given the low feasibility of targeted delivery of antibodies into the lungs by intravenous administration and the short half-life period of antibodies in the lungs by intranasal or aerosolized immunization, mRNA encoding broadly neutralizing antibodies with lung-targeting capability can perfectly provide high-titer antibodies in lungs to prevent the SARS-CoV-2 infection. Here, we firstly identify a human monoclonal antibody, 8-9D, with broad neutralizing potency against SARS-CoV-2 variants. The neutralization mechanism of this antibody is explained by the structural characteristics of 8-9D Fabs in complex with the Omicron BA.5 spike. In addition, we evaluate the efficacy of 8-9D using a safe and robust mRNA delivery platform and compare the performance of 8-9D when its mRNA is and is not selectively delivered to the lungs. The lung-selective delivery of the 8-9D mRNA enables the expression of neutralizing antibodies in the lungs which blocks the invasion of the virus, thus effectively protecting female K18-hACE2 transgenic mice from challenge with the Beta or Omicron BA.1 variant. Our work underscores the potential application of lung-selective mRNA antibodies in the prevention and treatment of infections caused by circulating SARS-CoV-2 variants.
Organizational Affiliation:
New Cornerstone Science Laboratory, Tsinghua-Peking Joint Center for Life Sciences, School of Medicine, Tsinghua University, Beijing, 100084, China.
